Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
The current ruling will assure the safety of the use of Ranitidine for Indian patients
EC grants conditional marketing authorization based on the EFFISAYIL trial
Subscribe To Our Newsletter & Stay Updated
